The TB research conducted by the Group consists of a broad range of studies including large-scale trials of treatment strategies for patients co-infected with TB and HIV to reduce mortality, studies to assess how new TB diagnostics can improve outcomes among TB suspects and patients, and the effect of earlier initiation of antiretroviral therapy (ART) in HIV-positive individuals on the incidence and prevalence of TB. Through its role as the Biostatistics Core of the Bill and Melinda Gates Foundation-funded Consortium to Respond Effectively to the AIDS and TB Epidemics (CREATE) programme, TEG was pivotal to the recent successful completion of two major cluster RCTs of interventions to control TB in HIV endemic settings. Results of these trials, the ZAMSTAR and Thibela TB studies, were presented at international meetings in 2011 and 2012 and published in peer-reviewed journals. We presented the findings of the OFLOTUB study, a Phase III study of a TB treatment-shortening regimen for drug sensitive TB, at an international meeting in late 2013, which is currently being written up for publication. The Group’s work on the RAFA project has been extended into 2014 and we hope to have initial results available in early 2015. The work of the Group continues to expand with a new 6-year cluster RCT soon to start in Lima, Peru. This is a socioeconomic intervention aiming to reduce further TB and mortality in TB-affected households.
Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, Hayes RJ, Chaisson RE, Grant AD, Thibela TB Study Team (2014) A trial of mass isoniazid preventive therapy for tuberculosis control. The New England Journal of Medicine, 370(4): 301-10. ISSN 0028-4793 DOI: 10.1056/NEJMoa1214289
Ayles H, Muyoyeta M, Du Toit E, Schaap A, Floyd S, Simwinga M, Shanaube K, Chishinga N, Bond V, Dunbar R, De Haas P, James A, Gey van Pittius NC, Claassens M, Fielding K, Fenty J, Sismanidis C, Hayes RJ, Beyers N, Godfrey-Faussett P; ZAMSTAR team (2013) Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial. Lancet 382(9899):1183-94. doi: 10.1016/S0140-6736(13)61131-9.
Staff working on Tuberculosis:
|Richard Hayes||James Lewis|
|Victoria Simms||Emily Webb|